Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
Abstract Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting protection against reinfection and durability of vaccine protection. Here, we longitudinally measured Spike (S) and Nucleocapsid (N)-specific antibodies in 1,309 healthcare workers (HCWs), including 916 COVID-19 negative HCWs and 393 convalescent COVID-19 for up to 422 days post-symptom. From month (M)1 to M7-9 post-infection, SARS-CoV-2 antibodies decreased moderately in convalescent HCWs in a biphasic model, with men showing a slower decay of anti-N (p=0.02), and a faster decay of anti-S (p=0.0008) than women. At M11-13, anti-N dramatically decreased (half-life: 283 days) while anti-S stabilized (half-life: 725 days) at a median of 2.39 log Arbitrary Units (AU)/mL (Interquartile Range (IQR): 2.10 -2.75). Overall, 69 SARS-CoV-2 infections developed in the COVID-19 negative group (incidence of 12.22 per 100 person-years) versus one in the COVID-19 positive group (incidence of 0.40 per 100 person-years), indicating a relative reduction in the incidence of SARS-CoV-2 reinfection of 96.7% (p<0.0001). Correlation with live-virus neutralization assay revealed that variants D614G and B.1.1.7, but not B.1.351, were sensitive to anti-S antibodies at 2.3 log AU/mL, while IgG ≥ 3 log AU/mL neutralized all three variants. After SARS-CoV-2 vaccination, anti-S levels reached at least 3 logs regardless of pre-vaccination IgG levels, type of vaccine, and number of doses. Our study demonstrates a long-term persistence of anti-S IgG antibodies that may protect against reinfection. By significantly increasing cross-neutralizing antibody titers, a single-dose vaccination strengthens protection against escape mutants.
Schmidt-Mutter Catherine、Fafi-Kremer Samira、Gantner Pierre、Wendling Marie-Jos¨|e、Bayer Sophie、Laugel Elodie、Reix Nathalie、Glady Ludovic、Collongues Nicolas、Lessinger Jean-Marc、Fontanet Arnaud、Hansmann Yves、Kling-Pillitteri Laurence、Bruel Timoth¨|e、Velay Aurelie、Solis Morgane、Planas Delphine、Gonzalez Maria、Gallais Floriane、Schneider Anne、De S¨¨ze J¨|rome、Rey David、Schwartz Olivier、Panaget Baptiste、Meyer Nicolas、Partisani Marialuisa
Centre d?ˉinvestigation Clinique INSERM 1434Virology Laboratory, Strasbourg University Hospital||Strasbourg UniversityVirology Laboratory, Strasbourg University Hospital||Strasbourg UniversityVirology Laboratory, Strasbourg University HospitalCHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Mol¨|culaireVirology Laboratory, Strasbourg University Hospital||Strasbourg UniversityCHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Mol¨|culaireCHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Mol¨|culaireCentre d?ˉinvestigation Clinique INSERM 1434CHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Mol¨|culaireEmerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur||PACRI Unit, Conservatoire National des Arts et M¨|tiersCHU de Strasbourg, Service des infectieuses et tropicalesCHU de Strasbourg, Service de Pathologies ProfessionnellesVirus & Immunity Unit, Department of Virology, Institut Pasteur||CNRS UMR 3569||Vaccine Research InstituteVirology Laboratory, Strasbourg University Hospital||Strasbourg UniversityVirology Laboratory, Strasbourg University Hospital||Strasbourg UniversityVirus & Immunity Unit, Department of Virology, Institut Pasteur||CNRS UMR 3569||Vaccine Research InstituteCHU de Strasbourg, Service des infectieuses et tropicalesVirology Laboratory, Strasbourg University Hospital||Strasbourg UniversityCHU de Strasbourg, D¨|partement de G¨|n¨|tique Mol¨|culaire du cancerCentre d?ˉinvestigation Clinique INSERM 1434CHU de Strasbourg, Trait d?ˉUnionVirus & Immunity Unit, Department of Virology, Institut Pasteur||CNRS UMR 3569||Vaccine Research InstituteVirology Laboratory, Strasbourg University Hospital||Strasbourg UniversityCHU de Strasbourg, Service de sant¨| PubliqueCHU de Strasbourg, Trait d?ˉUnion
医学研究方法预防医学基础医学
Schmidt-Mutter Catherine,Fafi-Kremer Samira,Gantner Pierre,Wendling Marie-Jos¨|e,Bayer Sophie,Laugel Elodie,Reix Nathalie,Glady Ludovic,Collongues Nicolas,Lessinger Jean-Marc,Fontanet Arnaud,Hansmann Yves,Kling-Pillitteri Laurence,Bruel Timoth¨|e,Velay Aurelie,Solis Morgane,Planas Delphine,Gonzalez Maria,Gallais Floriane,Schneider Anne,De S¨¨ze J¨|rome,Rey David,Schwartz Olivier,Panaget Baptiste,Meyer Nicolas,Partisani Marialuisa.Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection[EB/OL].(2025-03-28)[2025-05-05].https://www.medrxiv.org/content/10.1101/2021.05.07.21256823.点此复制
评论